Cally-GB 300mg/750mcg Tablet
Product Info
Prescription required | Yes |
Marketer | Shinto Organics (P) Limited |
Active Ingredient | Gabapentin (300mg) + Methylcobalamin (750mcg) |
Storage | Store below 30°C |
Habit Forming | No |
Therapeutic Class | NEURO CNS |
User Rating | 4.5 |
User Reviews | 621 |
FAQ
Cally-GB 300mg/750mcg Tablet Reviews
Cally-GB 300mg/750mcg is taken by mouth with or without food, preferably at bedtime. It is advised to take medicine at the same time each day as this helps to maintain a consistent level of medicine in the body. Take this medicine in the dose and duration advised by your doctor. If you miss a dose of this medicine, take it as soon as you remember. Finish the full course of treatment even if you feel better. It is important that this medication is not stopped suddenly without talking to the doctor.
Some common side effects of this medicine are nausea, peripheral edema, ataxia, blurred vision, fever and nystagmus (involuntary eye movement). It may also cause dizziness and sleepiness, so do not drive or do anything that requires mental focus until you know how this medicine affects you. It is important to inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression, or suicidal thoughts.
Before taking the medicine you should tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding. It can usually be mixed safely with other medicines but some drugs (including antacids and alcohol) do affect the way it works and can increase the chance of side effects.
How Cally-GB 300mg/750mcg Tablet Works
How to Use Cally-GB 300mg/750mcg Tablet
Benefits of Cally-GB 300mg/750mcg Tablet
- In Treatment of Neuropathic pain: Cally-GB 300mg/750mcg is a combination of medicines used to treat long-lasting (chronic) pain caused by nerve damage due to diabetes, shingles or spinal cord injury. It reduces pain and its associated symptoms such as mood changes, sleep problems, and tiredness. It is thought to work by interfering with pain signals that travel through the damaged nerves and the brain. Using this medicine regularly will improve your physical and social functioning and overall quality of life. It takes a few weeks to work so you need to use it regularly even if you feel it is not doing any good. Once your symptoms have gone you should still keep using the medicine until your doctor advises you to stop.
Uses of Cally-GB 300mg/750mcg Tablet
- Treatment of Neuropathic pain
Cally-GB 300mg/750mcg Tablet Side Effects
Safety Tips
Quick Tips
- Avoid consuming alcohol when taking Cally-GB 300mg/750mcg, as it may cause excessive sleepiness.
- You have been prescribed Cally-GB 300mg/750mcg for treating and preventing nerve pain.
- Inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression or suicidal thoughts or behavior.
- Its side effects are usually mild and temporary.
- To lower the chances of feeling dizzy or passing out, rise slowly if you have been sitting or lying down.
- It may cause dizziness or sleepiness. Do not drive or do anything requiring concentration until you know how it affects you.
- Do not stop taking the medication suddenly without talking to your doctor.
References
- Porters RJ, Meldrum BS. Antiseizure Drugs. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 410.
- Arlak Biotech. Methylcobalamin+gabapentin [Product Information].
- PubChem. Methylcobalamin hydrate.
- McNamara JO. Pharmacotherapy of the Epilepsies. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 599.
- Combs Jr. GF, McClung JP. The Vitamins: Fundamental Aspects in Nutrition and Health. 5th ed. Westborough, MA: Academic Press; 2017.
- Stahl SM, editor. Gabapentin. In: Stahl's Essential Pschopharmacology: Prescriber's Guide. 5th ed. New York, New York: Cambridge University Press; 2014. pp. 275-77.